WallStreetZenWallStreetZen

NYSE: DBD
Diebold Nixdorf Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for DBD

Based on 1 analyst offering 12 month price targets for Diebold Nixdorf Inc.
Min Forecast
$50.00+12.26%
Avg Forecast
$50.00+12.26%
Max Forecast
$50.00+12.26%

Should I buy or sell DBD stock?

Based on 1 analyst offering ratings for Diebold Nixdorf Inc.
Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their DBD stock forecasts and price targets.

DBD stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-05-03

1 of 1

Forecast return on equity

Is DBD forecast to generate an efficient return?
Insufficient data to display

Forecast return on assets

Is DBD forecast to generate an efficient return on assets?
Insufficient data to display

DBD revenue forecast

What is DBD's revenue in the next 2 years based on estimates from 1 analyst?
Avg 1 year Forecast
$3.8B
Avg 2 year Forecast
$3.9B

DBD vs App Stocks

TickerPricePrice TargetUp/downsideConsensus
DBD$44.54$50.00+12.26%Buy
GRND$9.48$13.33+40.64%Strong Buy
SOUN$5.05$6.88+36.24%Buy
SPT$29.93$54.25+81.26%Buy
UPBD$32.58$42.00+28.91%Strong Buy
View Top App Stocks

Diebold Nixdorf Stock Forecast FAQ

Is Diebold Nixdorf Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NYSE: DBD) stock is to Buy DBD stock.

Out of 1 analyst, 0 (0%) are recommending DBD as a Strong Buy, 1 (100%) are recommending DBD as a Buy, 0 (0%) are recommending DBD as a Hold, 0 (0%) are recommending DBD as a Sell, and 0 (0%) are recommending DBD as a Strong Sell.

If you're new to stock investing, here's how to buy Diebold Nixdorf stock.

What is DBD's revenue growth forecast for 2024-2025?

(NYSE: DBD) Diebold Nixdorf's forecast annual revenue growth rate of N/A is not forecast to beat the US Software - Application industry's average forecast revenue growth rate of 9.94%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.09%.

Diebold Nixdorf's revenue in 2024 is N/A.On average, 1 Wall Street analysts forecast DBD's revenue for 2024 to be $143,602,345,097, with the lowest DBD revenue forecast at $143,602,345,097, and the highest DBD revenue forecast at $143,602,345,097.

In 2025, DBD is forecast to generate $147,937,538,584 in revenue, with the lowest revenue forecast at $147,937,538,584 and the highest revenue forecast at $147,937,538,584.

What is DBD's forecast return on assets (ROA) for 2024-2025?

(NYSE: DBD) forecast ROA is N/A, which is lower than the forecast US Software - Application industry average of 3.47%.

What is DBD's Price Target?

According to 1 Wall Street analyst that have issued a 1 year DBD price target, the average DBD price target is $50.00, with the highest DBD stock price forecast at $50.00 and the lowest DBD stock price forecast at $50.00.

The Wall Street analyst predicted that Diebold Nixdorf's share price could reach $50.00 by May 3, 2025. The average Diebold Nixdorf stock price prediction forecasts a potential upside of 12.26% from the current DBD share price of $44.54.

What is DBD's forecast return on equity (ROE) for 2024-2025?

(NYSE: DBD) forecast ROE is N/A, which is considered weak.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.